Actively Recruiting
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-GC
Led by Shanghai Minimally Invasive Surgery Center · Updated on 2025-07-22
250
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in gastric cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.
CONDITIONS
Official Title
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-GC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy controls must be older than 18 years.
- Healthy controls must sign informed consent and agree to participate.
- Gastric cancer patients must be 18 years or older.
- Gastric cancer patients must have a performance status (ECOG) score of 1 or less.
- Gastric cancer patients must have histopathologically confirmed gastric adenocarcinoma.
- Gastric cancer patients must have no family history of hereditary cancer.
- Gastric cancer patients must have had no prior anti-tumor treatment.
- Gastric cancer patients must provide primary tumor tissue from surgery or biopsy meeting submission requirements.
- Gastric cancer patients must provide peripheral blood samples meeting submission requirements.
- Gastric cancer patients must be willing and able to sign informed consent to participate.
You will not qualify if you...
- Healthy controls at high risk for hereditary colorectal adenocarcinoma or with family history of gastrointestinal tumors, familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or Peutz-Jeghers syndrome.
- Healthy controls with difficult-to-control chronic metabolic or inflammatory diseases such as hypertension, diabetes, chronic viral hepatitis, or inflammatory bowel disease.
- Healthy controls with other malignancies that progressed or required treatment within past 5 years, except cured skin basal cell or squamous cell carcinoma.
- Healthy controls who used broad-spectrum antibiotics or probiotics orally or intravenously within past month.
- Healthy controls with regular use of immunosuppressive drugs within past 6 months.
- Healthy controls with long-term use of medications affecting metabolism, such as hormones.
- Healthy controls unable or unwilling to cooperate with follow-up visits and examinations.
- Healthy controls unable to eat normally or requiring medications/enemas for bowel movements.
- Healthy controls with psychiatric disorders or severe cardiovascular diseases.
- Healthy controls who are pregnant, breastfeeding, or planning pregnancy within next year.
- Healthy controls currently participating in interventional clinical studies or receiving study treatments affecting decisions.
- Gastric cancer patients currently in interventional clinical studies or receiving study treatments affecting decisions.
- Gastric cancer patients with other malignancies progressed or treated within past 5 years except cured skin basal cell or squamous cell carcinoma.
- Gastric cancer patients with difficult-to-control chronic metabolic or inflammatory diseases such as hypertension, diabetes, chronic viral hepatitis, or inflammatory bowel disease.
- Gastric cancer patients with poorly controlled chronic comorbidities affecting prognosis.
- Gastric cancer patients with psychiatric disorders or severe cardiovascular diseases.
- Gastric cancer patients who are pregnant, breastfeeding, or planning pregnancy within next year.
- Gastric cancer patients with long-term use of medications affecting metabolism such as hormones, immunosuppressants, or antibiotics.
- Gastric cancer patients with severe or uncontrolled medical conditions affecting participation or study results, as judged by investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin hospital Shanghai Jiaotong University, School of Medicine , Shanghai, Shanghai 200025
Shanghai, China
Actively Recruiting
Research Team
J
Jing Sun
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here